347 related articles for article (PubMed ID: 28236297)
1. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
Johansen N; Liavaag AH; Iversen OE; Dørum A; Braaten T; Michelsen TM
Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
Vermeulen RFM; Beurden MV; Kieffer JM; Bleiker EMA; Valdimarsdottir HB; Massuger LFAG; Mourits MJE; Gaarenstroom KN; van Dorst EBL; van der Putten HWHM; Aaronson NK
Eur J Cancer; 2017 Oct; 84():159-167. PubMed ID: 28818705
[TBL] [Abstract][Full Text] [Related]
3. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
Johansen N; Liavaag AH; Tanbo TG; Dahl AA; Pripp AH; Michelsen TM
Gynecol Oncol; 2016 Jan; 140(1):101-6. PubMed ID: 26597462
[TBL] [Abstract][Full Text] [Related]
4. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
Vermeulen RFM; Korse CM; Kenter GG; Brood-van Zanten MMA; Beurden MV
Climacteric; 2019 Aug; 22(4):352-360. PubMed ID: 30905183
[No Abstract] [Full Text] [Related]
5. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
6. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
[TBL] [Abstract][Full Text] [Related]
7. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
Gaba F; Blyuss O; Chandrasekaran D; Osman M; Goyal S; Gan C; Izatt L; Tripathi V; Esteban I; McNicol L; Ragupathy K; Crawford R; Evans DG; Legood R; Menon U; Manchanda R
BJOG; 2021 Mar; 128(4):714-726. PubMed ID: 32803845
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
9. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
Terra L; Lee Meeuw Kjoe PR; Agelink van Rentergem JA; Beekman MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mourits MJE; van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; van der Wall E; van Leeuwen FE; Schagen SB
BJOG; 2023 Jul; 130(8):968-977. PubMed ID: 36715559
[TBL] [Abstract][Full Text] [Related]
13. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
[TBL] [Abstract][Full Text] [Related]
14. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
Maturitas; 2016 Mar; 85():42-8. PubMed ID: 26857878
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
[TBL] [Abstract][Full Text] [Related]
16. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.
Michelsen TM; Dørum A; Tropé CG; Fosså SD; Dahl AA
Int J Gynecol Cancer; 2009 Aug; 19(6):1029-36. PubMed ID: 19820364
[TBL] [Abstract][Full Text] [Related]
17. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Hollenstein J; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
J Clin Oncol; 2006 Aug; 24(22):3576-82. PubMed ID: 16877724
[TBL] [Abstract][Full Text] [Related]
18. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience.
Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA
Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397
[TBL] [Abstract][Full Text] [Related]
19. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.
Michelsen TM; Dørum A; Dahl AA
Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933
[TBL] [Abstract][Full Text] [Related]
20. WHAM-A Prospective Study of Weight and Body Composition After Risk-Reducing Bilateral Salpingo-oophorectomy.
Price SAL; Finch S; Krejany E; Jiang H; Kale A; Domchek S; Wrede D; Wark JD; Hickey M
J Clin Endocrinol Metab; 2023 Dec; 109(1):e397-e405. PubMed ID: 37410931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
